x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:00:00

Management of HR+, HER2- High-Risk EBC

CME/CE ·

2024/12/30

Host: Erica L. Mayer, MD, MPH Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on

en

00:00:00

First-line Treatment of MSI-H/dMMR mCRC: The Role of...

CME/CE ·

2024/12/30

Host: Aparna R. Parikh, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and

en

00:00:00

Immunotherapy for TNBC in the Perioperative Setting:...

CME/CE ·

2024/12/30

Host: Peter Schmid, FRCP, MD, PhD Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on

en

00:00:00

Biomarker-Directed Approaches for Frontline Treatment...

CME/CE ·

2024/12/30

Host: Sara Lonardi, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and

en

00:00:00

Clinical Implications of Current Guidelines on...

CME/CE ·

2024/12/30

Host: Peter Schmid, FRCP, MD, PhD Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on

en

00:00:00

Expert Opinion: Key Insights on GI...

CME/CE ·

2024/12/30

Host: Sara Lonardi, MD Host: Aparna R. Parikh, MD Host: Alan Venook, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the

en

00:00:00

Applying Current Guidelines in the First-Line...

CME/CE ·

2024/12/30

Host: Aparna R. Parikh, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and

en

00:00:00

Immunotherapy-Based Approaches for First-Line...

CME/CE ·

2024/12/30

Host: Alan Venook, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and

en

00:00:00

Emerging Directions in Biomarker-Directed Therapy for...

CME/CE ·

2024/12/30

Host: Alan Venook, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and

en

00:00:00

The Role of Biomarker-Driven Therapies in the...

CME/CE ·

2024/12/30

Host: Sara Lonardi, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and

en

00:00:00

Emerging Treatment Approaches for EBC

CME/CE ·

2024/12/30

Host: William J. Gradishar, MD Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on

en

00:00:00

First-Line Advanced Gastric Cancer: Best Practices...

CME/CE ·

2024/12/30

Host: Sara Lonardi, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and

en

00:00:00

Current Guideline Recommendations for Biomarker-Based...

CME/CE ·

2024/12/30

Host: Aparna R. Parikh, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and

en

00:00:00

Guideline Recommendations for the Definition and...

CME/CE ·

2024/12/30

Host: Erica L. Mayer, MD, MPH Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on

en

00:00:00

Management of HER2-Low MBC Following First-Line...

CME/CE ·

2024/12/30

Host: Peter Schmid, FRCP, MD, PhD Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on

en

00:00:00

Novel Neoadjuvant and Adjuvant Immunotherapy...

CME/CE ·

2024/12/30

Host: Alan Venook, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and

en

00:00:00

The Role of HER2-Directed Therapy for Second-Line...

CME/CE ·

2024/12/30

Host: Peter Schmid, FRCP, MD, PhD Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on

en

00:00:00

Adjuvant Treatments for HR+/HER2- EBC: The Role of...

CME/CE ·

2024/12/30

Host: Erica L. Mayer, MD, MPH Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on

en

00:00:00

Unmasking IgAN: From Suspicion to Timely Diagnosis

CME/CE ·

2024/12/30

Host: Jörg Latus, MD Guest: Chee Kay Cheung, MBCHB, MRCP, PHD Because renal biopsy is required for diagnosis, providers must be able to identify the histopathological characteristics of IgA nephropathy and implement a systemic diagnostic approach. In addition, the mechanisms of action of some IgAN therapies may offer advantages over others in targeting specific pathways in disease pathophysiology. Join the experts for an exploration of these important clinical topics using a

en

00:00:00

Expert Viewpoint: Optimizing Breast Cancer Treatment

CME/CE ·

2024/12/30

Host: William J. Gradishar, MD Guest: Erica L. Mayer, MD, MPH Guest: Peter Schmid, FRCP, MD, PhD Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the

en

286 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事